Dexverapamil to overcome epirubicin resistance in advanced breast cancer
Beat Thürlimann(University of St.Gallen), M. Lehnert(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kurt R. Schumacher(University of Michigan), J. Hartlapp(Klinikum Osnabrück), Jochen Greiner(Kantonsspital St. Gallen), Guenther Gastl(Innsbruck Medical University), H. Küpper, K. Mross, Nicolaus Kröger(Universität Hamburg), J. Schüller(Saab (Switzerland)), Eva Schernhammer(Brigham and Women's Hospital)
Cited by 14
Related Papers
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study
|Journal of Clinical Oncology|2000|840
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
|Clinical Cancer Research|2015|799